date,title,source
Oct-17-18,"Investor Expectations to Drive Momentum within Arsanis, Dynavax Technologies, Puma Biotechnology, Opko Health, Adaptimmune Therapeutics, and Codexis  Discovering Underlying Factors of Influence",GlobeNewswire
Oct-18-18,Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results,Business Wire
Oct-18-18,Puma Biotech (PBYI) Rides High on Robust Nerlynx Performance,Zacks
Oct-25-18,Puma Biotech (PBYI) Q3 Earnings Preview: What to Look Out For,Zacks
Nov-01-18,"Puma Biotech (PBYI) Reports Q3 Loss, Tops Revenue Estimates",Zacks
Nov-01-18,Puma Biotech: 3Q Earnings Snapshot,Associated Press
Nov-01-18,"Why Puma Biotechnology, Inc. Stock Is Getting Crushed Today",Motley Fool
Nov-01-18,Puma Biotechnology Reports Third Quarter 2018 Financial Results,Business Wire
Nov-05-18,"Puma Biotech (PBYI) Q3 Loss Narrows, Nerlynx Pulls Stock Down",Zacks
Nov-07-18,Puma Biotechnology to Present at Credit Suisse Healthcare Conference,Business Wire
Nov-07-18,Biotech Stocks and the Midterm Elections,ACCESSWIRE
Nov-09-18,"Investor Expectations to Drive Momentum within Matson, Craft Brew Alliance, Easterly Government Properties, Novanta, Ascena Retail Group, and Puma Biotechnology  Discovering Underlying Factors of Influence",GlobeNewswire
Nov-15-18,Edited Transcript of PBYI earnings conference call or presentation 1-Nov-18 8:30pm GMT,Thomson Reuters StreetEvents
Nov-16-18,Edited Transcript of PBYI earnings conference call or presentation 1-Nov-18 8:30pm GMT,Thomson Reuters StreetEvents
Dec-03-18,Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),Business Wire
Dec-06-18,Here's Why Puma Biotechnology Tanked 37.3% in November,Motley Fool
Dec-06-18,Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium,Business Wire
Dec-06-18,"Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2018 San Antonio Breast Cancer Symposium",Business Wire
Dec-06-18,"Puma Biotechnology Presents Results from the Hormone Receptor Positive Subgroup in Phase III ExteNET Trial of Neratinib for HER2-Amplified, Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium",Business Wire
Dec-10-18,Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4),Business Wire
Dec-11-18,Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4),Business Wire
